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Abstract
Background: Several studies have investigated the involvement of nitric oxide (NO) in acute and chronic pain
using mice lacking a single NO synthase (NOS) gene among the three isoforms: neuronal (nNOS), inducible (iNOS)
and endothelial (eNOS). However, the precise role of NOS/NO in pain states remains to be determined owing to
the substantial compensatory interactions among the NOS isoforms. Therefore, in this study, we used mice lacking
all three NOS genes (n/i/eNOS
-/-mice) and investigated the behavioral phenotypes in a series of acute and chronic
pain assays.
Results: In a model of tissue injury-induced pain, evoked by intraplantar injection of formalin, both iNOS
-/-and n/i/
eNOS
-/-mice exhibited attenuations of pain behaviors in the second phase compared with that in wild-type mice. In
a model of neuropathic pain, nerve injury-induced behavioral and cellular responses (tactile allodynia, spinal
microglial activation and Src-family kinase phosphorylation) were reduced in n/i/eNOS
-/-but not iNOS
-/-mice. Tactile
allodynia after nerve injury was improved by acute pharmacological inhibition of all NOSs and nNOS. Furthermore,
in MG-5 cells (a microglial cell-line), interferon-g enhanced NOSs and Mac-1 mRNA expression, and the Mac-1
mRNA increase was suppressed by L-NAME co-treatment. Conversely, the NO donor, sodium nitroprusside,
markedly increased mRNA expression of Mac-1, interleukin-6, toll-like receptor 4 and P2X4 receptor.
Conclusions: Our results provide evidence that the NOS/NO pathway contributes to behavioral pain responses
evoked by tissue injury and nerve injury. In particular, nNOS may be important for spinal microglial activation and
tactile allodynia after nerve injury.
Background
Acute pain can act as an early warning device that alerts
us to the presence of damaging stimuli, e.g. trauma, che-
mical irritation and thermal stimuli. This pain usually goes
away soon after the noxious stimulus is removed. In con-
trast, chronic pain persists for a long time, and is categor-
ized into inflammatory pain and neuropathic pain.
Neuropathic pain, resulting from peripheral nerve injury,
is characterized by spontaneous pain, hyperalgesia and
allodynia [1]. Allodynia is nearly always resistant to known
treatments such as non-steroidal anti-inflammatory drugs
(NSAIDs) or even opioids. After nerve injury, spinal
microglia that are the main immunocompetent cells in the
central nervous system transform into an activated form.
Reactive microglia change their morphology and number,
and express several molecules such as interleukin (IL)-1b,
IL-6, interferon-g (IFN-g), toll-like receptor 4 (TLR4),
P2X4 receptor and nitric oxide synthases (NOSs) [2-6].
Therefore, glial cells, especially microglia, have received
much attention as a new therapeutic target for the treat-
ment of neuropathic pain. However, the mechanism of
neuropathic pain is not fully understood, and there are
currently no effective remedies.
Nitric oxide (NO) is a free radical that produces a vari-
ety of biological actions under physiological and patholo-
gical conditions [7-9] and is synthesized by three
isoforms of NOS: neuronal NOS (nNOS), inducible NOS
(iNOS) and endothelial NOS (eNOS) [10-12]. Previous
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acute and chronic pain using pharmacological procedures
or mice lacking a single NOS gene among the three iso-
forms. For instance, intraperitoneal administration of a
NO precursor or a NO donor potentiates thermal hyper-
algesia and tactile allodynia in neuropathic rats [13]. A
NOS inhibitor effectively improves tactile allodynia by
tight ligation of the fifth and sixth lumbar spinal nerves
in rats [14]. Moreover, nNOS
-/-mice fail to display nerve
injury-induced tactile hypersensitivity [15]. In contrast,
iNOS
-/-mice do not affect nerve injury-induced thermal
allodynia [16]. However, because there is a mechanism to
compensate for the quantity of NO in NOSs [17-19], the
precise role of endogenous NO still remains to be
determined.
In this study, we sought to investigate the role of the
NOS/NO pathway in models of acute and chronic pain
using mice lacking the iNOS gene (iNOS
-/-mice) and
mice lacking all three NOS genes (nNOS, iNOS and
eNOS triply-NOS
-/-mice: n/i/eNOS
-/-mice) [20]. Here,
we demonstrate that endogenous NO is a critical player
for inducing microglial activation in the spinal cord and
in pain hypersensitivity after peripheral nerve injury.
Furthermore, by using an MG-5 microglial cell-line, we
show that NO induces microglial activation. Taken
together, inhibition of NOS/NO signaling may be a
viable therapeutic strategy for treating neuropathic pain.
Results
Effect of NOS gene knockout on tissue injury- and
chemical-induced pain and acute mechanical and thermal
pain behavior responses
First, to examine the role of NOSs in physiological pain,
we assessed the acute and chronic pain responses follow-
ing injection of formalin into the hindpaw and intraperi-
toneal injection with acetic acid. After formalin injection,
wild-type (WT) mice displayed biphasic licking and bit-
ing behaviors: the first acute pain phase started immedi-
ately after injection and lasted for 5 min, and the second
persistent pain phase lasted for 60 min (see Figure 1A).
In contrast to WT mice, the magnitude of biphasic beha-
viors were significantly suppressed in iNOS
-/-mice (first
phase, P < 0.05; second phase, P < 0.05-0.01 vs. WT
mice; Figure 1A). Meanwhile, n/i/eNOS
-/-mice resulted in
a reduction of pain-related behavior in only the second
phase as compared with that in WT mice (second phase,
P < 0.05-0.01 vs. WT mice; Figure 1A). Interestingly,
when compared with iNOS
-/-mice but not with WT mice,
n/i/eNOS
-/-mice showed enhanced nociceptive responses
in the first phase and late second phase (after 35-60 min
of formalin injection) (first phase, P <0 . 0 1 ;l a t es e c o n d
phase, P <0 . 0 5v s .iNOS
-/-mice; first phase, P = 0.060;
late second phase, P = 0.143 vs. WT mice; Figure 1A). In
a test of innocuous mechanical stimuli applied by von
Frey filaments, both iNOS
-/-and n/i/eNOS
-/-mice were
indistinguishable from WT mice in terms of their paw
withdrawal thresholds (PWTs) (Figure 1B). In tail-flick
tests, the latencies for mice to flick their tails away from
radiant heat at both 30 V and 50 V were not different
between WT mice and n/i/eNOS
-/-mice, but only iNOS
-/-
mice showed a significant endurance of the noxious ther-
mal stimuli as compared with others (P <0 . 0 0 1v s .W T
mice and n/i/eNOS
-/-m i c e ;F i g u r e1 C ) .I nn/i/eNOS
-/-but
not in iNOS
-/-mice, the frequency of abdominal writhing
behaviors in response to intraperitoneal injection with
acetic acid, a model of chemical-induced visceral pain,
increased when compared with WT mice (P <0 . 0 5v s .
WT mice; Figure 1D).
Effect of NOS gene knockout on nerve injury-induced
tactile allodynia and spinal microglial activation
In WT mice, withdrawal threshold of the hindpaw ipsilat-
eral to the nerve injury markedly decreased (Figure 2A).
While iNOS
-/-mice displayed a similar pain response to
WT mice after nerve injury, the nerve injury-induced
decrease in PWT was significantly suppressed in n/i/
eNOS
-/-mice when compared with WT mice (day 1, 3, 5
and 10, P <0 . 0 1 ;d a y7a n d1 4 ,P <0 . 0 0 1v s .W Tm i c e ;
Figure 2A). In the contralateral hindpaw, both iNOS
-/-and
n/i/eNOS
-/-mice had a similar PWT to that in WT mice
(Figure 2B).
Spinal microglia are known to become activated after
nerve injury and play an important role in subsequent
pain hypersensitivity [2,21,22]. To examine the role of
NOSs in microglial activation, we performed immunos-
taining for ionized calcium binding adaptor molecule 1
(Iba1), a marker of microglia, in the spinal dorsal horn.
On day 14 after nerve injury, Iba1 immunoreactivity was
markedly enhanced in the ipsilateral dorsal horn in WT
mice as compared with that in the contralateral dorsal
horn. In the ipsilateral dorsal horn, the changes in mor-
phology of microglial cells after nerve injury (hypertro-
phy of cell body and retraction of processes) were
observed in WT mice and in iNOS
-/-mice but were
much less in n/i/eNOS
-/-mice (Figure 2C). The numbers
of ipsilateral Iba1
+ microglial cells after nerve injury
increased in all three types of mice, but the increase in
n/i/eNOS
-/-mice was significantly less when compared
with those in WT mice (P < 0.01) and in iNOS
-/-mice (P
< 0.05; Figure 2D). Neither morphology nor number of
Iba1
+ cells were altered in any three lines of mice in the
contralateral dorsal horn (Figure 2C, D).
Suppression in activation of Src-family kinases and
expression of IL-6 and TLR4 mRNA after spinal nerve
injury in n/i/eNOS
-/-mice
Src-family kinases (SFKs) have been reported to be acti-
vated in microglia in the spinal dorsal horn after nerve
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immunoreactivity of phosphorylated-SFKs (p-SFKs), an
active form, in the ipsilateral dorsal horn of WT mice
was observed on day 14 after spinal nerve injury. Nerve
injury-induced SFK phosphorylation was markedly sup-
pressed in n/i/eNOS
-/-but not iNOS
-/-mice (Figure 3A, B).
Moreover, expression of inflammatory cytokines and
plasma membrane receptors, such as IL-6, IL-1b,T N F - a
and TLR4, has been reported to be upregulated in the
spinal cord after nerve injury [3-5]. Interestingly, the
increase in IL-6 and TLR4 mRNA levels, but not IL-1b
and TNF-a (data not shown), were significantly reduced
in n/i/eNOS
-/-mice (P < 0.05 both vs. WT mice; Figure
3C, D). We have now examined the levels of P2X4R
mRNA expression in the spinal cord on day 14 after
nerve injury by a real-time PCR analysis. In WT mice,
P2X4R mRNA level was increased in 1.61 ± 0.51-fold in
the ipsilateral spinal cord as compared with that in the
contralateral side. Similarly, 1.61 ± 0.46-fold increase of
P2X4R mRNA was observed in iNOS
-/-mice. The upregu-
lation of P2X4R mRNA expression was tendency to be
suppressed in n,i, eNOS
-/-mice (0.77 ± 0.42-fold increase;
P = 0.282 vs. WT mice, P = 0.247 vs. iNOS
-/-mice, n = 4).
Pharmacological inhibition of nNOS suppresses tactile
allodynia after spinal nerve injury
We tested the effects of NOS inhibitors on the develop-
ment and maintenance of nerve injury-induced tactile
Figure 1 Acute mechanical and thermal pain and inflammatory- and chemical-induced pain in iNOS
-/-and n/i/eNOS
-/-mice. (A) Formalin
test. Mice were injected intraplantarly with formalin (5% (v/v), 20 μL). Values represent the duration (sec) of licking and biting responses for each
5-min interval, from 0-5 min (1st phase), for 10-35 min (2nd-1 phase) and for 35-60 min (2nd-2 phase) (n = 8 animals/group). (B) Innocuous
mechanical stimuli test. Values indicate the threshold (g) to elicit paw withdrawal behavior in response to mechanical stimuli (WT mice and n/i/
eNOS
-/-mice, n =9 ,iNOS
-/-mice n = 8 animals) (C) Tail-flick test. Values represent the latency (sec) for animals to flick their tail away from the heat
source (n = 8 animals/group) (D) Visceral pain in response to acetic acid (0.8% (v/v)). Values represent the numbers of abdominal stretches
(writhes) (n = 8 animals/group). All data are presented as means ± SEM. Statistical analysis were determined by two-way repeated ANOVA (A) or
two-way ANOVA (B, C, D) with Tukey’s test, *P < 0.05, **P < 0.01 vs. WT mice, #P < 0.05, ##P < 0.01 vs. iNOS
-/-mice.
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G-nitro-
arginine methyl ester (L-NAME), a non-specific NOS
inhibitor, to rats once daily for 7 days, significantly sup-
pressed the decrease in ipsilateral PWT after nerve
injury in a dose-dependent manner without an effect on
the contralateral hindpaw (day 1, 3 and 7, P <0 . 0 0 1 ;
day 5, P < 0.01 100 mg/kg L-NAME vs. vehicle group in
ipsilateral; Figure 4A, B). Furthermore, acute intraperito-
neal administration of L-NAME and acute intrathecal
administration of 7-nitroindazole, a specific nNOS inhi-
bitor, reversed tactile allodynia on day 7 after
n e r v ei n j u r y( P < 0.05-0.001 both vs. vehicle group; Fig-
ure 4C, D).
IFN-g activated in microglia via NOS/NO
IFN-g levels are known to increase in the spinal cord
after spinal nerve injury, and are implicated in microglial
activation and tactile allodynia [3,24]. To investigate the
Figure 2 Spinal nerve injury-induced tactile allodynia and microglial activation in iNOS
-/-and n/i/eNOS
-/-mice. PWTs (A; ipsilateral
hindpaw, B; contralateral hindpaw) of WT mice (n =9 ) ,iNOS
-/- mice (n =8 )a n dn/i/eNOS
-/-mice (n = 9) before (0) and 1, 3, 7, 10 and 14
days after fifth lumbar spinal nerve injury. All data are presented as means ± SEM. Statistical analysis were determined by two-way repeated
ANOVA with Tukey’st e s t ,* P <0 . 0 5 ,* * P < 0.01, *** P < 0.001 vs. WT mice. (C) Photomicrographs show immunostaining with Iba1, a marker
of microglia, in the fifth lumbar spinal dorsal horn of WT mice (a-c), iNOS
-/-mice (d-f) and n/i/eNOS
-/-mice (g-i) 14 days after nerve injury.
Scale bars: 200 μm (b, e, h) and 20 μm (a, c, d, f, g, i) (D) The number of Iba1
+microglia in the spinal dorsal horn (n =4a n i m a l s / g r o u p ) .A l l
data are presented as means ± SEM. Statistical analysis were determined by two-way ANOVA with Tukey’st e s t ,* P < 0.05, ***P < 0.001 vs.
contralateral, #P < 0.05, ##P < 0.01.
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microglial activation, we examined the effect of IFN-g
on microglial transcriptional alterations using MG-5
cells, a mouse microglial cell-line [25]. IFN-g induced a
significant increase in the expression of iNOS and
nNOS mRNA in a dose-dependent manner in MG-5
cells (39.3 ± 5.0-fold of iNOS and 5.32 ± 0.61-fold of
nNOS mRNA in 100 U/mL IFN-g as compared with
non-treatment; P < 0.001 both; Figure 5A, B).
Additionally, in IFN-g-stimulated MG-5 cells, Mac-1
mRNA expression levels, which are known to be upre-
gulated in activated microglia, were significantly
increased by 1.50 ± 0.16- and 1.61 ± 0.17-fold as com-
pared with non-treated MG-5 cells (P < 0.01; Figure
5C). This IFN-g-induced increase was attenuated to con-
trol levels by co-treatment with L-NAME (P < 0.05-
0.001; Figure 5C). Conversely, applying sodium nitro-
prusside (SNP) to MG-5 cells significantly increased
Figure 3 Reduction in the amount of p-SFKs in iNOS
-/-and n/i/eNOS
-/-mice, and changes in IL-6 and TLR4 mRNA expression levels in n/
i/eNOS
-/-mice. (A) Photomicrographs show immunostaining for phosphorylated-Src family kinases (p-SFKs) in the fifth lumbar spinal dorsal horn
of WT mice (a), iNOS
-/-mice (b) and n/i/eNOS
-/-mice (c) 14 days after spinal nerve injury. Scale bar: 200 μm. (B) Analysis of p-SFKs
immunoreactivity in the spinal dorsal horn of WT mice, iNOS
-/-mice and n/i/eNOS
-/-mice (n = 3 animals/group). (C, D) Levels of interleukin-6 (IL-6)
and toll-like receptor 4 (TLR4) mRNA expression. Expression of IL-6 and TLR4 were significantly increased in the ipsilateral spinal cord when
compared with the contralateral spinal cord in WT mice (n = 5) 14 days after nerve injury. In n/i/eNOS
-/-mice (n = 4), IL-6 (C) and TLR4 (D) mRNA
expression levels were significantly attenuated when compared with WT mice. All data are presented as a mean ± SEM. Statistical analysis was
determined by one-way ANOVA with Tukey’s test, **P < 0.01, #P < 0.05.
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(1.46 ± 0.09-fold in the presence of 1.0 mM SNP as
compared with the non-treatment group, P <0 . 0 1 ;F i g -
ure 6A). SNP also increased mRNA expression levels of
IL-6, TLR4 and P2X4 receptor in a dose-dependent
manner (10.8 ± 0.60-, 1.94 ± 0.14- and 1.67 ± 0.08-fold
i nt h ep r e s e n c eo f1 . 0m MS N Pa sc o m p a r e dw i t ht h e
non-treatment group; P < 0.001 each; Figure 6B-D).
Discussion
The present study provides the first evidence that n/i/
eNOS triple gene knockouts attenuate peripheral nerve
injury-induced tactile allodynia and spinal microglial acti-
vation. Moreover, activating the NOS/NO pathway can
promote expressions of microglial IL-6, TLR4 and P2X4
receptor, which are implicated in neuropathic pain [2-6].
Chronic pain is categorized into inflammatory pain,
induced by peripheral tissue inflammation, and neuro-
pathic pain, causing damage and malfunction of the
nerve system. The former can have adequate pain con-
trol by known analgesics, but the latter shows resistance
to existing treatments. We demonstrated that iNOS
-/-
mice showed suppression of formalin-induced acute and
persistent pain, but not nerve injury-induced neuro-
pathic pain as compared with WT mice. This result in
thermal hyperalgesia is consistent with a previous report
showing no attenuation of the nerve injury-induced
thermal hyperalgesia in iNOS-deficient mice [16]. In
contrast to the behavioral phenotype of iNOS
-/-mice in
the formalin test, the reduction of nociceptive behaviors
of n/i/eNOS
-/-mice was weak in the late second phase,
and in the first phase, n/i/eNOS
-/-mice facilitated the
nociceptive response. However, in a model of neuro-
pathic pain, tactile allodynia induced by nerve injury
was markedly inhibited only in n/i/eNOS
-/-mice. These
results suggest that NOS/NO signaling critically contri-
butes to both tissue injurious pain and neuropathic
pain, and that each NOS isoform has a different func-
tion in pain signaling. In previous studies, N-nitro-L-
arginine, a non-selective NOS inhibitor, reduces first
phase nociceptive behavior evoked by formalin, whereas
the iNOS inhibitor aminoguanidine and the nNOS inhi-
bitor 7-nitroindazole do not have a suppressing effect
on the first phase pain response [26]. Furthermore, an
Figure 4 Pharmacological inhibition of NOS/NO suppressed tactile allodynia after spinal nerve injury. (A, B) Effect of L-NAME, a non-
selective NOS inhibitor. PWTs (A; ipsilateral hindpaw, B; contralateral hindpaw) following intraperitoneal administration of L-NAME to rats once
daily before (0) and 1, 3, 5 and 7 days after fifth lumbar spinal nerve injury (n = 6 animals/group). (C) Effect of intraperitoneal (i.p.) administration
of L-NAME on the decrease in PWTs after 7 days of spinal nerve injury (n = 4 animals/group). (D) Effect of intraperitoneal (i.t.) administration of
7-nitroindazole (7-NI), a selective nNOS inhibitor, on the decrease in PWTs after 7 days of spinal nerve injury (n = 4 animals/group). All data are
presented as a mean ± SEM. Statistical analysis were determined by one-way repeated ANOVA (C) or two-way repeated ANOVA (A, B, D) with
Tukey’s test, *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle treatment, ###P < 0.001 vs. pre measurement.
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isoform, one of 10 splicing differentiations, has a signifi-
cant exacerbation effect against the first phase [27].
While the responses of innocuous mechanical stimuli
were indistinguishable between WT mice and the two
genotypes of NOS
-/-mice, the latency of tail flick away
from noxious heat stimuli was extended in iNOS
-/-mice,
but not n/i/eNOS
-/-mice. Acetic acid-induced visceral
pain was also enhanced in n/i/eNOS
-/-mice when com-
pared with WT mice. L-NAME has been reported to
have no effect on tail-flick test latencies, but L-NAME
and 7-nitroindazole inhibit acetic acid-induced writhing
behavior [28]. However, these previous reports illustrate
the complexity of NOS in pain perception; our data lead
to the hypothesis that nNOS and/or eNOS may have a
role in suppressing pain signaling.
Activation of spinal microglia is known to occur after
nerve injury [2,21,22]. Because minocycline, which inhi-
bits microglial activation in vivo [29], reduces tactile
allodynia on nerve injury [30], the microglial activated
restraint leads to pain relief in neuropathic pain states.
The activation of spinal microglia as well as tactile allo-
d y n i aa f t e rn e r v ei n j u r yw a ss u p p r e s s e di no n l yn/i/
eNOS
-/-mice. The suppression of nerve injury-induced
neuropathic pain responses in all NOSs-knockout mice
correlated with the reduction in the numerical and mor-
phological changes of microglia after nerve injury. These
results suggest that NOS/NO signaling participates in
neuropathic pain through activation of microglia.
We have previously shown that SFKs are activated in
the spinal cord after nerve injury. The SFKs are the lar-
gest family of nonreceptor tyrosine kinases and nine sub-
types have been identified: Src, Yes, Fyn, Fgr, Lck, Hck,
Blk, Lyn and Frk [31]. We have also showed previously
that Lyn is predominantly expressed in microglia.
Because transcriptional activity of microglial P2X4 recep-
tor mRNA is reduced in a neuropathic pain model using
Lyn
-/-mice [23], the increase of spinal p-SFKs may result
in an enhancement of microglial transcriptional activity
in response to nerve injury. After spinal nerve injury,
Figure 5 Increased expression of iNOS, nNOS and Mac-1 mRNA in microglial cell line cultures. Expression levels of iNOS (A) and nNOS (B)
mRNA in MG-5 microglial cell line cultures. These mRNA expression levels significantly increased following treatment with interferon-g (IFN-g)i n
a dose-dependent manor (n = 6 samples/group). In addition, (C) the expression levels of Mac-1 mRNA were significantly increased following IFN-
g exposure. This increase was attenuated by co-treatment with L-NAME (n = 6 samples/group). All data are presented as a mean ± SEM.
Statistical analysis was determined by one-way ANOVA with Tukey’s test, *P < 0.05, **P < 0.01, ***P < 0.001.
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IL-6, IL-1b,T N F - a and TLR4 [3-5]. In fact, IL-6 and
TLR4 mRNA transcriptional activities increased after
nerve injury, and these increases were inhibited in n/i/
eNOS
-/-mice, which observed a significant degrease of p-
SFKs immunoreactivity. P2X4R mRNA expression was
also tendency to be reduced in n/i/eNOS
-/-mice. It is pos-
s i b l et h a tN O S / N Os i g n a l i n gm a yb ei n v o l v e di ne x p r e s -
sion of these cytokine/receptor transcripts, presumably
through microglial SFK activation after spinal nerve
injury. It was reported that the intrathecal administration
of the anti-IL-6 antibody attenuates nerve injury-induced
tactile allodynia and microglial activation in rats [32].
Additionally, spinal nerve injury-induced tactile allodynia
and microglial activation are inhibited in TLR4
-/-mice [3].
IL-6 and TLR4 have been implicated in neuropathic pain
conditions. Therefore, it is conceivable that suppressing
expression of these molecules in microglia may be
involved in the attenuation of nerve injury-induced tactile
allodynia observed in n/i/eNOS
-/-mice.
Expression of NOS and NO are known to be markedly
upregulated in damaged nerves, dorsal root ganglia and
glial cells in the spinal dorsal horn after nerve injury
[33,34]. Our pharmacological procedure indicated the
chronic intraperitoneal administration of L-NAME sup-
pressed the development of tactile allodynia. Further-
more, acute administrations of L-NAME or 7-
nitroindazole reversed established tactile allodynia on
day 7 after nerve injury. It has been reported that nNOS
knockout mice can attenuate neuropathic pain [15].
Because a previous study has shown that intracerebro-
ventricular administration of 7-nitroindazole has no
effect on alleviating pain in the chronic constriction
injury model [13], nNOS in the brain may have a minor
role in nerve injury-induced allodynia. These results
suggest that NOS/NO signaling plays a key role in neu-
ropathic pain states, and spinal or peripheral nNOS
plays an important role in tactile allodynia during devel-
opment and maintenance. There is no evidence that
eNOS precisely contributes to neuropathic pain,
although eNOS expression is upregulated in the injured
sciatic nerve [35].
IFN-g is reported to induce microglial activation and
neuropathic pain through Lyn and P2X4 receptor signal-
ing [24]. In our in vitro study, expression of iNOS and
nNOS mRNA were increased in IFN-g-treated MG-5
cells. In IFN-g- or SNP-treated MG-5 cells, the signifi-
cant increase in the expression of Mac-1, known as a
Figure 6 Microglial activation, and increased IL-6, TLR4 and P2X4 receptor mRNA expression levels via NO. Expression levels of Mac-1
(A), interleukin-6 (IL-6; B), toll-like receptor 4 (TLR4; C) and P2X4 receptor (P2X4R; D) mRNA in MG-5 microglial cell line cultures. mRNA expression
levels were significant increased by treatment with sodium nitroprusside (SNP), a NO donor (n = 6 samples/group). All data are presented as a
mean ± SEM. Statistical analysis was determined by one-way ANOVA with Tukey’s test, *P < 0.05, **P < 0.01, ***P < 0.001.
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g-induced increase in Mac-1 mRNA expression was pre-
vented by L-NAME co-treatment. From these results, it
is possible that IFN-g upregulates iNOS and nNOS
expression, which in turn promotes activation of micro-
glial cells (although it is likely that the role of iNOS in
neuropathic pain may be relatively minor because a
marked attenuation of allodynia was not observed in
iNOS
-/-mice compared with n/i/eNOS
-/-mice). IL-6 and
TLR4 expression, which were attenuated in n/i/eNOS
-/-
mice with spinal nerve injury, and P2X4 receptor
mRNA were increased following SNP treatment. Upre-
gulation of the P2X4 receptor in microglia is an impor-
tant process in producing neuropathic pain [2]. P2rx4
-/-
mice do not show nerve injury-induced tactile hypersen-
sitivity [36]. Thus, in addition to IL-6 and TLR4, the
P2X4 receptor may also be involved in the suppression
of tactile allodynia in n/i/eNOS
-/-mice.
Conclusions
In summary, we demonstrate that the NOS/NO pathway
plays an important role in the development and mainte-
nance of neuropathic pain after nerve injury. Pharmaco-
l o g i ca n dg e n e t i cs t u d i e si n d i c a t et h a ts p i n a la n d / o r
peripheral NOS, especially nNOS, contributes to upre-
gulation of IL-6, TLR4 and P2X4 receptor expression
through microglial SFK activation. These findings are
conducive to the understanding of the neuropathic pain
mechanism.
Methods
Animals
All experimental procedures were performed in accor-
dance with institutional guidelines at Kyushu University
regarding the care and use of animals. Male iNOS
knockout mice (iNOS
-/-mice), male n/i/eNOS triple
knockout mice (n/i/eNOS
-/-mice) and male C57BL/6J
WT mice (the genomic status of each mouse was
checked) were used in the present study [20]. Male
C57BL/6J mice (25-35 g) were bought from Japan SLC
(Hamamatsu, Japan). Mice were housed at a constant
temperature of 22 ± 1°C with a 12-hour light-dark cycle
(lights on between 08:30 and 20:30), and had ad libitum
access to food and water.
Behavioral assays for acute and chronic pain
In the test of formalin-induced pain, mice were injected
intraplantarly with formalin (5% (v/v), 20 μL), and the
duration of licking and biting responses to the injected
hindpaw were recorded at 5 min intervals for 60 min
after injection (formalin pain) [36]. Noxious heat-evoked
tail and hindpaw withdrawal responses were detected by
the application of radiant heat (Ugo Basile, Italy) to the
tail and the plantar surface of the hindpaw, respectively
[36]. The intensity of the heat stimulus was adjusted to
30 or 50 V, and the latency of the tail withdrawal
response (sec) was measured. The sensitivity to mechan-
ical stimuli was assessed using von Frey filaments
(0.02-2.0 g, Stoelting, Wood Dale, IL, USA), and
the mechanical stimulus producing a 50% PWT was
determined using the up-down method [37,38]. In the
chemical visceral pain test, mice were injected intraperi-
toneally with acetic acid (0.8% (v/v)), and the number of
abdominal writhes was counted for 5 min starting from
5 min after the injection [36].
Spinal nerve injury-induced neuropathic pain model
The spinal nerve injury model in mice was produced as
described previously [23,39]. For the experiments using
mice, the left fifth lumbar spinal nerve of mice was
transacted under 2% (v/v) isofluorane anesthesia.
Immunohistochemistry
T h em i c ew e r ea n e s t h e t i z e db yp e n t o b a r b i t a l( 1 0 0m g /
kg, intraperitoneally) and perfused transcardially with
4% (w/v) paraformaldehyde. The fifth lumbar segment
of the lumbar spinal cord was quickly removed, post-
fixed in the same fixative, and placed in 30% (w/v)
sucrose solution for 24 hrs at 4°C. Immunohistochemis-
try and analysis of transverse spinal cord sections (30
μm) were performed in accordance with methods
described previously [40]. The rabbit anti-ionized cal-
cium binding adaptor molecule 1 (anti-Iba1) antibody
(1:2,000, Wako, Osaka, Japan) was used as the primary
antibody, and the anti-rabbit immunoglobulin G (IgG)-
conjugated Alexa Fluor 488 (1:1,000, Molecular Probes,
Eugene, OR, USA) was used as the secondary antibody.
The intensity of p-SFKs immunoreactivity was analyzed
using a software Photoshop CS3 (Adobe, San Jose, CA).
Drug administration
Phosphate buffered saline (PBS; as a vehicle control) or L-
N
G-nitro-arginine methyl ester (L-NAME) (Sigma, St.
Louis, MO, USA; 30 or 100 mg/kg) was intraperitoneally
administered to rats once a day for 7 days with a 26 G
needle. Measurement of PWT was performed on 0, 1, 3, 5
and 7 days after administration. For intrathecal drug
administration, under 2% (v/v) isofluorane anesthesia,
mice were injected with a 32 G needle. After peripheral
nerve injury, rats were administered intrathecally with PBS
(5 μL, as a vehicle control) or L-NAME (100 mg/kg) at
day 7 after nerve injury. Measurement of PWT was per-
formed at 0.5, 1, 1.5, 2, 3, 6 and 12 hrs after administra-
tion. Similarly, 7-nitroindazole (Calbiochem, Darmstadt,
Germany; 3 or 10 μgi n5μL) was intrathecally adminis-
tered and measurement of PWT was performed at 0.5, 1,
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administration was performed just after pre-measurement,
and PWT was measured at each time point.
MG-5 Culture
The MG-5 mouse microglial cell line was cultured as
described previously by Ohsawa et al. [25]. Conditioned
medium from the supernatant of A1 cells cultured over-
night in Dulbecco’s modified Eagle’sm e d i u m( I n v i t r o -
gen, Carlsbad, CA, USA) containing 10% (v/v) fetal
bovine serum, penicillin and streptomycin (20 U/mL)
w a su s e da st h ec u l t u r em e d i u mf o rM G - 5c e l l s .M G - 5
cells were exposed to IFN-g and SNP for 1 hr under
serum-free conditions.
Real-time reverse transcription-PCR
The fifth lumbar spinal cord was quickly removed. Total
RNA preparation and real-time RT-PCR amplification/
detection were performed in accordance with methods
described previously [40]. All expression values were nor-
malized by the expression values of 18S ribosomal RNA.
The TaqMan probe and the forward and reverse primers
used in this study were designed according to Table 1.
Ribosomal RNA was measured using TaqMan Ribosomal
RNA Control Reagents (P/N 4308329, Applied Biosys-
tems, Carlsbad, CA, USA). The TaqMan probe and pri-
mers for Mac-1 were obtained from Applied Biosystems.
Statistical analysis
Data are expressed as the means ± SEM. Statistical ana-
lyses of the results were conducted with one-way
ANOVA, one-way repeated ANOVA, two-way ANOVA
or two-way repeated ANOVA with a post hoc test
(Tukey’s multiple comparison test). Statistical signifi-
cance was set at a P value < 0.05.
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